{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:05:53Z","timestamp":1790741153334,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Neuropsychiatric symptoms including agitation, delirium, and psychosis are common in patients with primary or metastatic brain tumors and frequently necessitate antipsychotic treatment. Brain tumors create a hyperexcitable cortical environment characterized by glutamatergic excess, impaired inhibitory signaling, peritumoral edema, network disruption, and treatment-related neurotoxicity, all of which lower seizure threshold. Emerging data further implicates impaired astrocytic glutamate regulation, neuroligin-3\u2013mediated neuron\u2013glioma synaptic signaling, and IDH-mutant\u2013associated oncometabolite accumulation as contributors to cortical instability. Neuropsychiatric symptoms often localize to frontal and temporal networks that are also highly epileptogenic, amplifying vulnerability. Brain tumor\u2013related epilepsy further compounds this risk through recurrent seizures, interictal dysfunction, and antiseizure medication effects that contribute to cognitive and behavioral disturbance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>In general psychiatric populations, second-generation antipsychotics have low intrinsic seizure liability. However, these data largely exclude patients with structural brain disease. In neuro-oncology, seizure risk is context-dependent and reflects the interaction of tumor biology, antiseizure medication exposure, metabolic instability, and dynamic treatment effects. Clozapine and low-potency first-generation antipsychotics confer the greatest seizure risk, whereas risperidone and aripiprazole are associated with lower risk. Commonly used antiseizure medications, particularly levetiracetam, may exacerbate irritability and behavioral dysregulation, increasing the need for antipsychotic treatment within an already unstable neurophysiologic environment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review synthesizes evidence on tumor-associated hyperexcitability, antipsychotic-specific seizure liability, and clinical modifiers of risk in brain tumor populations. We propose a seizure-informed, interdisciplinary framework that integrates tumor biology, antiseizure medication selection, and psychiatric indication to guide antipsychotic prescribing in neuro-oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11920-026-01696-y","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:56:18Z","timestamp":1783929378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antipsychotics and Seizure Risk in Patients with Brain Tumors: Mechanisms, Modifiers, and Clinical Insights"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8188-546X","authenticated-orcid":false,"given":"Fawad","family":"Taj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert B.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesne","family":"Alici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"1696_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1480900","volume":"15","author":"M Maschio","year":"2024","unstructured":"Maschio M, Perversi F, Maialetti A. Brain tumor-related epilepsy: an overview on neuropsychological, behavioral, and quality of life issues and assessment methodology. Front Neurol. 2024;15:1480900. https:\/\/doi.org\/10.3389\/fneur.2024.1480900.","journal-title":"Front Neurol"},{"issue":"2","key":"1696_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3988\/jcn.2023.0501","volume":"20","author":"JS Kim","year":"2024","unstructured":"Kim JS, Hong SB, Park KW, Lee ATC. Psychotic symptoms in patients with major neurological diseases. J Clin Neurol. 2024;20(2):153\u201365. https:\/\/doi.org\/10.3988\/jcn.2023.0501.","journal-title":"J Clin Neurol"},{"issue":"9","key":"1696_CR3","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/pon.4787","volume":"27","author":"S Subramaniam","year":"2018","unstructured":"Subramaniam S, Kong YC, Chinna K, et al. Health-related quality of life and psychological distress among cancer survivors in a middle-income country. Psychooncology. 2018;27(9):2172\u20139. https:\/\/doi.org\/10.1002\/pon.4787.","journal-title":"Psychooncology"},{"issue":"2","key":"1696_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10943-016-0267-y","volume":"56","author":"GC Ng","year":"2017","unstructured":"Ng GC, Mohamed S, Sulaiman AH, Zainal NZ. Anxiety and depression in cancer patients: the association with religiosity and religious coping. J Relig Health. 2017;56(2):575\u201390. https:\/\/doi.org\/10.1007\/s10943-016-0267-y.","journal-title":"J Relig Health"},{"issue":"1","key":"1696_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/noad154","volume":"26","author":"EK Avila","year":"2024","unstructured":"Avila EK, Tobochnik S, Inati SK, et al. Brain tumor-related epilepsy management: a Society for Neuro-oncology (SNO) consensus review on current management. Neuro Oncol. 2024;26(1):7\u201324. https:\/\/doi.org\/10.1093\/neuonc\/noad154.","journal-title":"Neuro Oncol"},{"issue":"9","key":"1696_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1212\/WNL.0b013e318266fa89","volume":"79","author":"TI Yuen","year":"2012","unstructured":"Yuen TI, Morokoff AP, Bjorksten A, et al. Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology. 2012;79(9):883\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e318266fa89.","journal-title":"Neurology"},{"issue":"10","key":"1696_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm.2453","volume":"17","author":"SC Buckingham","year":"2011","unstructured":"Buckingham SC, Campbell SL, Haas BR, et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011;17(10):1269\u201374. https:\/\/doi.org\/10.1038\/nm.2453.","journal-title":"Nat Med"},{"issue":"17","key":"1696_CR8","first-page":"4383","volume":"1","author":"ZC Ye","year":"1999","unstructured":"Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res Sep. 1999;1(17):4383\u201391.","journal-title":"Cancer Res Sep"},{"issue":"24","key":"1696_CR9","doi-asserted-by":"publisher","first-page":"10767","DOI":"10.1523\/JNEUROSCI.19-24-10767.1999","volume":"19","author":"ZC Ye","year":"1999","unstructured":"Ye ZC, Rothstein JD, Sontheimer H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci. 1999;19(24):10767\u201377. https:\/\/doi.org\/10.1523\/JNEUROSCI.19-24-10767.1999.","journal-title":"J Neurosci"},{"issue":"7673","key":"1696_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nature24014","volume":"549","author":"HS Venkatesh","year":"2017","unstructured":"Venkatesh HS, Tam LT, Woo PJ, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 2017;549(7673):533\u20137. https:\/\/doi.org\/10.1038\/nature24014.","journal-title":"Nature"},{"key":"1696_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jocn.2015.11.030","volume":"31","author":"Y Yang","year":"2016","unstructured":"Yang Y, Mao Q, Wang X, et al. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy. J Clin Neurosci. 2016;31:56\u201362. https:\/\/doi.org\/10.1016\/j.jocn.2015.11.030.","journal-title":"J Clin Neurosci"},{"issue":"3","key":"1696_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3171\/2020.7.JNS201042","volume":"1","author":"TP Gupte","year":"2021","unstructured":"Gupte TP, Li C, Jin L, et al. Clinical and genomic factors associated with seizures in meningiomas. J Neurosurg Sep. 2021;1(3):835\u201344. https:\/\/doi.org\/10.3171\/2020.7.JNS201042.","journal-title":"J Neurosurg Sep"},{"issue":"6","key":"1696_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrclinonc.2011.58","volume":"8","author":"AF Eichler","year":"2011","unstructured":"Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344\u201356. https:\/\/doi.org\/10.1038\/nrclinonc.2011.58.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1696_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/02688697.2023.2170326","volume":"39","author":"E Vacher","year":"2025","unstructured":"Vacher E, Rodriguez Ruiz M, Rees JH. Management of brain tumour related epilepsy (BTRE): a narrative review and therapy recommendations. Br J Neurosurg. 2025;39(1):4\u201311. https:\/\/doi.org\/10.1080\/02688697.2023.2170326.","journal-title":"Br J Neurosurg"},{"key":"1696_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.806839","volume":"12","author":"F Dono","year":"2021","unstructured":"Dono F, Consoli S, Evangelista G, et al. Levetiracetam prophylaxis therapy for brain tumor-related epilepsy (BTRE) is associated with a higher psychiatric burden. Front Neurol. 2021;12:806839. https:\/\/doi.org\/10.3389\/fneur.2021.806839.","journal-title":"Front Neurol"},{"key":"1696_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.euroneuro.2022.12.010","volume":"68","author":"L Reichelt","year":"2023","unstructured":"Reichelt L, Efthimiou O, Leucht S, Schneider-Thoma J. Second-generation antipsychotics and seizures - a systematic review and meta-analysis of serious adverse events in randomized controlled trials. Eur Neuropsychopharmacol. 2023;68:33\u201346. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.12.010.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1696_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/WCO.0b013e32833e996c","volume":"23","author":"AO Rossetti","year":"2010","unstructured":"Rossetti AO, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol. 2010;23(6):603\u20139. https:\/\/doi.org\/10.1097\/WCO.0b013e32833e996c.","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"1696_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","volume":"6","author":"MS van Breemen","year":"2007","unstructured":"van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421\u201330. https:\/\/doi.org\/10.1016\/S1474-4422(07)70103-5.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1696_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/archneurol.2010.2","volume":"67","author":"JW Lee","year":"2010","unstructured":"Lee JW, Wen PY, Hurwitz S, et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010;67(3):336\u201342. https:\/\/doi.org\/10.1001\/archneurol.2010.2.","journal-title":"Arch Neurol"},{"issue":"6","key":"1696_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/CCO.0b013e32833de99d","volume":"22","author":"R Ruda","year":"2010","unstructured":"Ruda R, Trevisan E, Soffietti R. Epilepsy and brain tumors. Curr Opin Oncol. 2010;22(6):611\u201320. https:\/\/doi.org\/10.1097\/CCO.0b013e32833de99d.","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"1696_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11864-024-01182-8","volume":"25","author":"HB Newton","year":"2024","unstructured":"Newton HB, Wojkowski J. Antiepileptic strategies for patients with primary and metastatic brain tumors. Curr Treat Options Oncol. 2024;25(3):389\u2013403. https:\/\/doi.org\/10.1007\/s11864-024-01182-8.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"1696_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00002018-200629020-00001","volume":"29","author":"FM Besag","year":"2006","unstructured":"Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf. 2006;29(2):95\u2013118. https:\/\/doi.org\/10.2165\/00002018-200629020-00001.","journal-title":"Drug Saf"},{"issue":"Suppl 2","key":"1696_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1528-1157.2002.043s2037.x","volume":"43","author":"E Spina","year":"2002","unstructured":"Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 2002;43(Suppl 2):37\u201344. https:\/\/doi.org\/10.1046\/j.1528-1157.2002.043s2037.x.","journal-title":"Epilepsia"},{"key":"1696_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.phrs.2016.03.022","volume":"107","author":"M Mula","year":"2016","unstructured":"Mula M. The pharmacological management of psychiatric comorbidities in patients with epilepsy. Pharmacol Res. 2016;107:147\u201353. https:\/\/doi.org\/10.1016\/j.phrs.2016.03.022.","journal-title":"Pharmacol Res"},{"issue":"4","key":"1696_CR25","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2025.70","volume":"11","author":"M Mula","year":"2025","unstructured":"Mula M, Kanner AM, Young AH, Di Giorgio A, Schulze-Bonhage A, Trinka E. Epilepsy and psychosis: navigating through a complex intersection. BJPsych Open. 2025;11(4):e127. https:\/\/doi.org\/10.1192\/bjo.2025.70.","journal-title":"BJPsych Open"},{"key":"1696_CR26","doi-asserted-by":"publisher","unstructured":"Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol. 2016;17(12):e529\u2013e541. https:\/\/doi.org\/10.1016\/S1470-2045(16)30571-X.","DOI":"10.1016\/S1470-2045(16)30571-X"},{"key":"1696_CR27","doi-asserted-by":"publisher","unstructured":"Pour-Rashidi A, Namvar M, Iranmehr A, Carpaneto A, Hanaei S, Rezaei N. Psychological and Psychiatric Aspects of Brain and Spinal Cord Tumors. Adv Exp Med Biol. 2023;1405:673\u201387. https:\/\/doi.org\/10.1007\/978-3-031-23705-8_26.","DOI":"10.1007\/978-3-031-23705-8_26"},{"key":"1696_CR28","doi-asserted-by":"publisher","unstructured":"Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis ofFood and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. Aug 15 2007;62(4):345\u201354. https:\/\/doi.org\/10.1016\/j.biopsych.2006.09.023.","DOI":"10.1016\/j.biopsych.2006.09.023"},{"key":"1696_CR29","doi-asserted-by":"publisher","unstructured":"Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25(2):91\u2013110. https:\/\/doi.org\/10.2165\/00002018-200225020-00004.","DOI":"10.2165\/00002018-200225020-00004"},{"key":"1696_CR30","doi-asserted-by":"publisher","unstructured":"Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, Garcia M, Aguirre C. Antipsychotics and seizures: higher risk with atypicals? Seizure. Mar 2013;22(2):141\u20133. https:\/\/doi.org\/10.1016\/j.seizure.2012.10.009.","DOI":"10.1016\/j.seizure.2012.10.009"},{"key":"1696_CR31","doi-asserted-by":"publisher","unstructured":"Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure. 2010;19(2):69\u201373. https:\/\/doi.org\/10.1016\/j.seizure.2009.11.005.","DOI":"10.1016\/j.seizure.2009.11.005"},{"key":"1696_CR32","doi-asserted-by":"publisher","unstructured":"Detyniecki K. Do Psychotropic Drugs Cause Epileptic Seizures? A Review of the Available Evidence. Curr Top Behav Neurosci. 2022;55:267\u201379. https:\/\/doi.org\/10.1007\/7854_2021_226.","DOI":"10.1007\/7854_2021_226"},{"key":"1696_CR33","doi-asserted-by":"publisher","unstructured":"Gopaul M, Altalib H. Do psychotropic drugs cause seizures? Epilepsy Behav Rep. 2024;27:100679. https:\/\/doi.org\/10.1016\/j.ebr.2024.100679.","DOI":"10.1016\/j.ebr.2024.100679"},{"key":"1696_CR34","doi-asserted-by":"publisher","unstructured":"Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991;41(3):369\u201371. https:\/\/doi.org\/10.1212\/wnl.41.3.369.","DOI":"10.1212\/wnl.41.3.369"},{"key":"1696_CR35","doi-asserted-by":"publisher","unstructured":"Varma S, Bishara D, Besag FM, Taylor D. Clozapine-related EEG changes and seizures: dose and plasmalevel relationships. Ther Adv Psychopharmacol. 2011;1(2):47\u201366. https:\/\/doi.org\/10.1177\/2045125311405566.","DOI":"10.1177\/2045125311405566"},{"key":"1696_CR36","doi-asserted-by":"publisher","unstructured":"Bloechliger M, Ruegg S, Jick SS, Meier CR, Bodmer M. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis. CNS Drugs. 2015;29(7):591\u2013603. https:\/\/doi.org\/10.1007\/s40263-015-0262-y.","DOI":"10.1007\/s40263-015-0262-y"},{"key":"1696_CR37","doi-asserted-by":"publisher","unstructured":"Citraro R, Leo A, Aiello R, Pugliese M, Russo E, De Sarro G. Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats. Neurotherapeutics. 2015;12(1):250\u201362. https:\/\/doi.org\/10.1007\/s13311-014-0318-6.","DOI":"10.1007\/s13311-014-0318-6"},{"key":"1696_CR38","doi-asserted-by":"publisher","unstructured":"Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29(9):971\u201385. https:\/\/doi.org\/10.1016\/j.euroneuro.2019.06.008.","DOI":"10.1016\/j.euroneuro.2019.06.008"},{"key":"1696_CR39","doi-asserted-by":"publisher","unstructured":"Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324\u201361. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.11.032.","DOI":"10.1016\/j.neubiorev.2021.11.032"},{"key":"1696_CR40","doi-asserted-by":"publisher","unstructured":"Hirsch S, Steinert T. The Use of Rapid Tranquilization in Aggressive Behavior. Dtsch Arztebl Int. 2019;116(26):445\u201352. https:\/\/doi.org\/10.3238\/arztebl.2019.0445.","DOI":"10.3238\/arztebl.2019.0445"},{"key":"1696_CR41","doi-asserted-by":"publisher","unstructured":"Pompili M, Ducci G, Galluzzo A, Rosso G, Palumbo C, De Berardis D. The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review. Int J Environ Res Public Health. 2021;18(8). https:\/\/doi.org\/10.3390\/ijerph18084368.","DOI":"10.3390\/ijerph18084368"},{"key":"1696_CR42","doi-asserted-by":"publisher","unstructured":"Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology. 1996;46(4):985\u201391. https:\/\/doi.org\/10.1212\/wnl.46.4.985.","DOI":"10.1212\/wnl.46.4.985"},{"issue":"11","key":"1696_CR43","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/neuonc\/noab152","volume":"23","author":"T Walbert","year":"2021","unstructured":"Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021;23(11):1835\u201344. https:\/\/doi.org\/10.1093\/neuonc\/noab152.","journal-title":"Neuro Oncol"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-026-01696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-026-01696-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-026-01696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:02:18Z","timestamp":1783972938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-026-01696-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1696"],"URL":"https:\/\/doi.org\/10.1007\/s11920-026-01696-y","relation":{},"ISSN":["1535-1645"],"issn-type":[{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}